Sugi Predict

Sugi Predict / Targets / BAD

BAD

Bcl2-associated agonist of cell death · Q92934 · BAD on Sugi Atlas →

27,510 patent compounds predicted against BAD, 21,267 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Sanguinarium Sanguinarium (SCHEMBL123241) 1.00 7/20
Sanguinarium Sanguinarium (SCHEMBL43290) 0.97 7/20
Sanguinarium Sanguinarium (SCHEMBL454298) 0.88 7/20
SCHEMBL543021 SCHEMBL543021 0.56 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL423231) 0.50 7/20
SCHEMBL685145 SCHEMBL685145 0.92 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL891377) 0.66 4/20
SCHEMBL891378 SCHEMBL891378 0.65 4/20
Navitoclax Navitoclax (SCHEMBL522847) 1.00 3/20
SCHEMBL316521 SCHEMBL316521 0.46 3/20
SCHEMBL554039 SCHEMBL554039 0.45 3/20
SCHEMBL554040 SCHEMBL554040 0.45 3/20
SCHEMBL554894 SCHEMBL554894 0.43 3/20
SCHEMBL554895 SCHEMBL554895 0.43 3/20
SCHEMBL555011 SCHEMBL555011 0.43 3/20
SCHEMBL295702 SCHEMBL295702 0.43 3/20
SCHEMBL666445 SCHEMBL666445 0.42 3/20
SCHEMBL554105 SCHEMBL554105 0.41 3/20
SCHEMBL554106 SCHEMBL554106 0.41 3/20
SCHEMBL554673 SCHEMBL554673 0.38 3/20

Clinical trials — most relevant to BAD by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma PHASE4UNKNOWN
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL PHASE2RECRUITING
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
SPC2996 in Chronic Lymphocytic Leukaemia PHASE1/PHASE2COMPLETED
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS) PHASE2COMPLETED
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme PHASE2COMPLETED
Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia PHASE2UNKNOWN
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer PHASE1COMPLETED
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors PHASE1UNKNOWN
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN PHASE1ACTIVE_NOT_RECRUITING
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects PHASE1COMPLETED
Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients PHASE1COMPLETED
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) PHASE1COMPLETED
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer PHASE1UNKNOWN
Dexanabinol in Patients With Brain Cancer PHASE1COMPLETED
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders PHASE1COMPLETED
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome PHASE1COMPLETED
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML nanRECRUITING
Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors nanCOMPLETED
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission nanRECRUITING
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries nanCOMPLETED
Impact of CASP3 Gene in Chemoresistance nanNOT_YET_RECRUITING
The Effect of TRA-8 on Ovarian Cancer Tissue nanCOMPLETED
Dietary Intervention With High Phenolic EVOO in CLL nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a BAD binder may also engage these)

ProteinNameSimilarity
Q61337 — 1.000 Q61337 →
Q8C5P7 — 1.000 Q8C5P7 →
O35147 — 0.999 O35147 →
P09512 — 0.997 P09512 →
P17523 — 0.996 P17523 →
Q8NG27 — 0.994 Q8NG27 →
P13200 — 0.994 P13200 →
F5HI87 — 0.994 F5HI87 →
Q8LT05 — 0.994 Q8LT05 →
P28925 — 0.993 P28925 →
Q6S6U0 — 0.993 Q6S6U0 →
P17524 — 0.993 P17524 →
A1A5P0 — 0.993 A1A5P0 →
Q7XT42 — 0.993 Q7XT42 →
Q05536 — 0.993 Q05536 →
P43598 — 0.993 P43598 →
Q86YL5 — 0.993 Q86YL5 →
Q14493 — 0.993 Q14493 →
Q53QW1 — 0.992 Q53QW1 →
O14015 — 0.992 O14015 →
Q91W92 — 0.992 Q91W92 →
Q9JM96 — 0.992 Q9JM96 →
Q9Y6B2 — 0.992 Q9Y6B2 →
Q8QVM1 — 0.992 Q8QVM1 →
E9PSU6 — 0.991 E9PSU6 →
P03209 — 0.991 P03209 →
Q9SK92 — 0.991 Q9SK92 →
Q4JQW6 — 0.991 Q4JQW6 →
Q8BRE0 — 0.991 Q8BRE0 →
Q6SW03 — 0.991 Q6SW03 →